Cantor Fitzgerald Sticks to Its Buy Rating for Marinus (MRNS)


In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Marinus (MRNS), with a price target of $19. The company’s shares closed on Friday at $5.46.

Piros observed:

“: We are reiterating our Overweight rating and $19/share 12- month price target on Marinus. the FDA Advisory Committee voted 17-1 in favor of benefits outweighing risks (as outlined in the FDA’s proposed Therapeutics’s (SAGE – NC) ZULRESSO (brexanolone) for the treatment of postpartum depression (PPD). As a reminder, Sage uses a similar mechanism of action as Marinus’s ganaxolone, but ganaxolone could possibly be safer (due to an added methyl group). We highlight below our takeaways from the meeting (and how this relates to Marinus), noting that a majority of the discussion was focused on safety, clinical benefit, infusion settings, and dosing regimens.”

According to TipRanks.com, Piros has currently no stars on a ranking scale of 0-5 stars, with an average return of -7.4% and a 38.8% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.

Marinus has an analyst consensus of Moderate Buy, with a price target consensus of $16, a 193.0% upside from current levels. In a report issued on October 29, Mizuho Securities also maintained a Buy rating on the stock with a $13 price target.

.

See today’s analyst top recommended stocks >>

Based on Marinus’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.11 million. In comparison, last year the company had a GAAP net loss of $4.17 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts